Brain Cancer | Clinical

ODAC Votes Against Omburtamab for Neuroblastoma with CNS/ Leptomeningeal Metastases

October 28, 2022

In a unanimous vote, the FDA’s Oncologic Drugs Advisory Committee has voted that there is not enough evidence to conclude omburtamab improves overall survival in neuroblastoma with central nervous system/leptomeningeal metastases.